{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:56:52Z","timestamp":1740149812497,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s12328-021-01423-5","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T17:02:40Z","timestamp":1620320560000},"page":"1202-1210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Spontaneous reactivation of hepatitis B virus with a frameshift mutation in the precore region in an elderly hepatitis B virus carrier with lifestyle-related diseases"],"prefix":"10.1007","volume":"14","author":[{"given":"Satoshi","family":"Takakusagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5924-1170","authenticated-orcid":false,"given":"Hitoshi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yozo","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Kizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Marubashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kosone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3419-6297","authenticated-orcid":false,"given":"Kazumoto","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0827-0964","authenticated-orcid":false,"given":"Hiroaki","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"key":"1423_CR1","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"A Schweitzer","year":"2015","unstructured":"Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546\u201355.","journal-title":"Lancet"},{"key":"1423_CR2","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hep.23327","volume":"51","author":"TT Chang","year":"2010","unstructured":"Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:422\u201330.","journal-title":"Hepatology"},{"key":"1423_CR3","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/hep.22841","volume":"49","author":"DJ Tenney","year":"2009","unstructured":"Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na\u00efve patients is rare through 5 years of therapy. Hepatology. 2009;49:1503\u201314.","journal-title":"Hepatology"},{"key":"1423_CR4","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/hep.26686","volume":"59","author":"KM Kitrinos","year":"2014","unstructured":"Kitrinos KM, Corsa A, Liu Y, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2014;59:434\u201342.","journal-title":"Hepatology"},{"key":"1423_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","volume":"1","author":"HL Chan","year":"2016","unstructured":"Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:185\u201395.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1423_CR6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","volume":"1","author":"M Buti","year":"2016","unstructured":"Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196\u2013206.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1423_CR7","doi-asserted-by":"crossref","unstructured":"Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update. Hepatol Res. 2020; 50: 892\u2013923.","DOI":"10.1111\/hepr.13504"},{"key":"1423_CR8","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/hep.1840070416","volume":"7","author":"MJ Tong","year":"1987","unstructured":"Tong MJ, Sampliner RE, Govindarajan S, et al. Spontaneous reactivation of hepatitis B in Chinese patients with HBsAg-positive chronic active hepatitis. Hepatology. 1987;7:713\u20138.","journal-title":"Hepatology"},{"key":"1423_CR9","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1159\/000490099","volume":"12","author":"DH Kim","year":"2018","unstructured":"Kim DH, Kim SB. Hepatic failure by spontaneous reactivation of hepatitis B virus without a trigger factor in a patient with anti-HBs. Case Rep Gastroenterol. 2018;12:286\u201391.","journal-title":"Case Rep Gastroenterol"},{"key":"1423_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.4254\/wjh.v5.i7.387","volume":"5","author":"K Zachou","year":"2013","unstructured":"Zachou K, Sarantopoulos A, Gatselis NK, et al. Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: a hidden threat. World J Hepatol. 2013;5:387\u201392.","journal-title":"World J Hepatol"},{"key":"1423_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1055\/s-0033-1345722","volume":"33","author":"D Shouval","year":"2013","unstructured":"Shouval D, Shibolet O. Immunosuppression and HBV reactivation. Semin Liver Dis. 2013;33:167\u201377.","journal-title":"Semin Liver Dis"},{"key":"1423_CR12","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/jmv.24115","volume":"87","author":"H Kamitsukasa","year":"2015","unstructured":"Kamitsukasa H, Iri M, Tanaka A, et al. Spontaneous reactivation of hepatitis B virus (HBV) infection in patients with resolved or occult HBV infection. J Med Virol. 2015;87:589\u2013600.","journal-title":"J Med Virol"},{"key":"1423_CR13","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00705-010-0628-x","volume":"155","author":"Mulyanto","year":"2010","unstructured":"Mulyanto, Depamede SN, Surayah K, et al. Identification and characterization of novel hepatitis B virus subgenotype C10 in Nusa Tenggara. Indonesia Arch Virol. 2010;155:705\u201315.","journal-title":"Indonesia. Arch Virol"},{"key":"1423_CR14","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1128\/jvi.64.3.1298-1303.1990","volume":"64","author":"H Okamoto","year":"1990","unstructured":"Okamoto H, Yotsumoto S, Akahane Y, et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol. 1990;64:1298\u2013303.","journal-title":"J Virol"},{"key":"1423_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jcv.2012.06.011","volume":"55","author":"J Inoue","year":"2012","unstructured":"Inoue J, Ueno Y, Kawamura K, et al. Association between S21 substitution in the core protein of hepatitis B virus and fulminant hepatitis. J Clin Virol. 2012;55:147\u201352.","journal-title":"J Clin Virol"},{"key":"1423_CR16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2957\/kanzo.47.279","volume":"47","author":"R Nakao","year":"2006","unstructured":"Nakao R, Yatsuhashi H, Myoji M, et al. Discrimination between acute hepatitis B and acute exacerbations of chronic hepatitis B by measurement of IgM class antibody to hepatitis B core antigen by CLIA method. Kanzo. 2006;47:279\u201382 ((In Japanese)).","journal-title":"Kanzo"},{"key":"1423_CR17","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1053\/jhep.2001.28708","volume":"34","author":"J Hou","year":"2001","unstructured":"Hou J, Wang Z, Cheng J, et al. Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology. 2001;34:1027\u201334.","journal-title":"Hepatology"},{"key":"1423_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25730","author":"M Raheel","year":"2020","unstructured":"Raheel M, Choga WT, Blackard JT. The distribution of hepatitis B virus surface antigen polymorphisms at positions associated with vaccine escape. J Med Virol. 2020. https:\/\/doi.org\/10.1002\/jmv.25730.","journal-title":"J Med Virol"},{"key":"1423_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1743-422X-11-9","volume":"11","author":"R Pei","year":"2014","unstructured":"Pei R, Grund S, Verheyen J, et al. Spontaneous reactivation of hepatitis B virus replication in an HIV coinfected patient with isolated anti-Hepatitis B core antibodies. Virol J. 2014;11:9.","journal-title":"Virol J"},{"key":"1423_CR20","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/00007890-200207270-00007","volume":"74","author":"PM Chen","year":"2002","unstructured":"Chen PM, Yao NS, Wu CM, et al. Detection of reactivation and genetic mutations of the hepatitis B virus in patients with chronic hepatitis B infections receiving hematopoietic stem cell transplantation. Transplantation. 2002;74:182\u20138.","journal-title":"Transplantation"},{"key":"1423_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s12185-009-0359-5","volume":"90","author":"S Kusumoto","year":"2009","unstructured":"Kusumoto S, Tanaka Y, Mizokami M, et al. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol. 2009;90:13\u201323.","journal-title":"Int J Hematol"},{"key":"1423_CR22","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/hep.21249","volume":"44","author":"A Ozasa","year":"2006","unstructured":"Ozasa A, Tanaka Y, Orito E, et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology. 2006;44:326\u201334.","journal-title":"Hepatology"},{"key":"1423_CR23","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1136\/gut.52.11.1630","volume":"52","author":"T Imamura","year":"2003","unstructured":"Imamura T, Yokosuka O, Kurihara T, et al. Distribution of hepatitis B viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba. Japan Gut. 2003;52:1630\u20137.","journal-title":"Japan Gut"},{"key":"1423_CR24","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/j.1872-034X.2009.00519.x","volume":"39","author":"A Kusakabe","year":"2009","unstructured":"Kusakabe A, Tanaka Y, Mochida S, et al. Case-control study for the identification of virological factors associated with fulminant hepatitis B. Hepatol Res. 2009;39:648\u201356.","journal-title":"Hepatol Res"},{"key":"1423_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.virusres.2016.04.022","volume":"220","author":"L Koumbi","year":"2016","unstructured":"Koumbi L, Pollicino T, Raimondo G, et al. Hepatitis B virus basal core promoter mutations show lower replication fitness associated with cccDNA acetylation status. Virus Res. 2016;220:150\u201360.","journal-title":"Virus Res"},{"key":"1423_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.virusres.2010.10.013","volume":"155","author":"RA Lizzano","year":"2011","unstructured":"Lizzano RA, Yang B, Clippinger AJ, et al. The C-terminal region of the hepatitis B virus X protein is essential for its stability and function. Virus Res. 2011;155:231\u20139.","journal-title":"Virus Res"},{"key":"1423_CR27","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.virusres.2012.02.013","volume":"165","author":"N Luo","year":"2012","unstructured":"Luo N, Cai Y, Zhang J, Tang W, et al. The C-terminal region of the hepatitis B virus X protein is required for its stimulation of HBV replication in primary mouse hepatocytes. Virus Res. 2012;165:170\u20138.","journal-title":"Virus Res"},{"key":"1423_CR28","doi-asserted-by":"publisher","first-page":"10554","DOI":"10.1128\/JVI.00661-06","volume":"80","author":"H Li","year":"2006","unstructured":"Li H, Chi CY, Lee S, Andrisani OM. The mitogenic function of hepatitis B virus X protein resides within amino acids 51 to 140 and is modulated by N- and C-terminal regulatory regions. J Virol. 2006;80:10554\u201364.","journal-title":"J Virol"},{"key":"1423_CR29","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1093\/carcin\/bgn111","volume":"29","author":"X Liu","year":"2008","unstructured":"Liu X, Wang L, Zhang S, et al. Mutations in the C-terminus of the X protein of hepatitis B virus regulate Wnt-5 expression in hepatoma Huh7 cells: cDNA microarray and proteomic analyses. Carcinogenesis. 2008;29:1207\u201314.","journal-title":"Carcinogenesis"},{"issue":"67","key":"1423_CR30","first-page":"370","volume":"2017","author":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL. Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;2017(67):370\u201398.","journal-title":"J Hepatol"},{"key":"1423_CR31","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560\u201399.","journal-title":"Hepatology"},{"key":"1423_CR32","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2169\/internalmedicine.5678-20","volume":"60","author":"T Hara","year":"2021","unstructured":"Hara T, Oka K, Iwai N, et al. Hepatitis B virus reactivation 55 months following chemotherapy including rituximab and autologous peripheral blood stem cell transplantation for malignant lymphoma. Intern Med. 2021;60:417\u201321.","journal-title":"Intern Med."}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-021-01423-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-021-01423-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-021-01423-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T16:25:38Z","timestamp":1626971138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-021-01423-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1423"],"URL":"https:\/\/doi.org\/10.1007\/s12328-021-01423-5","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"type":"print","value":"1865-7257"},{"type":"electronic","value":"1865-7265"}],"subject":[],"published":{"date-parts":[[2021,5,6]]},"assertion":[{"value":"9 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights"}},{"value":"Informed consent was obtained from all patients included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}